tirzepatide weight loss nejm A 3-year study of in participants with obesity and prediabetes showed substantial and sustained reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 SURMOUNT-1 (NEJM 2022) tested tirzepatide
Pay in 4 interest-free payments of $7.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7






















